Silapo

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
25-11-2020
产品特点 产品特点 (SPC)
25-11-2020
公众评估报告 公众评估报告 (PAR)
21-03-2019

有效成分:

epoetin zeta

可用日期:

Stada Arzneimittel AG

ATC代码:

B03XA01

INN(国际名称):

epoetin zeta

治疗组:

Antianemic preparations

治疗领域:

Anemia; Blood Transfusion, Autologous; Cancer; Kidney Failure, Chronic

疗效迹象:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patientsTreatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis.Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre‑existing anaemia at the start of chemotherapy).Silapo can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Silapo is indicated for non-iron deficient adults prior to major elective orthopaedic surgery having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1 800 ml).Silapo can be used to increase haemoglobin concentration in symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (

產品總結:

Revision: 17

授权状态:

Authorised

授权日期:

2007-12-18

资料单张

                                66
B. PACKAGE LEAFLET
67
PACKAGE LEAFLET: INFORMATION FOR THE USER
SILAPO 1 000 IU/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 2 000 IU/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 3 000 IU/0.9 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 4 000 IU/0.4 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 5 000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 6 000 IU/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 8 000 IU/0.8 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 10 000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 20 000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 30 000 IU/0.75 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
SILAPO 40 000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin zeta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacist or
nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor, pharmacist, or
nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Silapo is and what it is used for
2.
What you need to know before you use Silapo
3.
How to use Silapo
4.
Possible side effects
5.
How to store Silapo
6.
Contents of the pack and other information
1.
WHAT SILAPO IS AND WHAT IT IS USED FOR
Silapo contains the active substance epoetin zeta – a protein, that
stimulates the bone marrow to
produce more red blood cells, which carry haemoglobin (a substance
that transports oxygen). Epoetin
zeta is a copy of the human protein erythropoietin
(ee-rith-roe-po-eh-tin) and acts in the same way.

SILAPO IS USED TO TREAT SYMPTOMATIC ANAEMIA CAUSED BY KIDNEY DISEASE

in ch
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Silapo 1 000 IU/0.3 mL solution for injection in pre-filled syringe
Silapo 2 000 IU/0.6 mL solution for injection in pre-filled syringe
Silapo 3 000 IU/0.9 mL solution for injection in pre-filled syringe
Silapo 4 000 IU/0.4 mL solution for injection in pre-filled syringe
Silapo 5 000 IU/0.5 mL solution for injection in pre-filled syringe
Silapo 6 000 IU/0.6 mL solution for injection in pre-filled syringe
Silapo 8 000 IU/0.8 mL solution for injection in pre-filled syringe
Silapo 10 000 IU/1 mL solution for injection in pre-filled syringe
Silapo 20 000 IU/0.5 mL solution for injection in pre-filled syringe
Silapo 30 000 IU/0.75 mL solution for injection in pre-filled syringe
Silapo 40 000 IU/1 mL solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Silapo 1 000 IU/0.3 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.3 mL solution for injection contains 1 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 3 333
IU epoetin zeta per mL.
_Excipient with known effect_
Each pre-filled syringe contains 0.15 mg phenylalanine.
Silapo 2 000 IU/0.6 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.6 mL solution for injection contains 2 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 3 333
IU epoetin zeta per mL.
_Excipient with known effect_
Each pre-filled syringe contains 0.30 mg phenylalanine.
Silapo 3 000 IU/0.9 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.9 mL solution for injection contains 3 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 3 333
IU epoetin zeta per mL.
_Excipient with known effect_
Each pre-filled syringe contains 0.45 mg phenylalanine.
Silapo 4 000 IU/0.4 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.4 mL solution for injec
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 25-11-2020
产品特点 产品特点 保加利亚文 25-11-2020
公众评估报告 公众评估报告 保加利亚文 21-03-2019
资料单张 资料单张 西班牙文 25-11-2020
产品特点 产品特点 西班牙文 25-11-2020
公众评估报告 公众评估报告 西班牙文 21-03-2019
资料单张 资料单张 捷克文 25-11-2020
产品特点 产品特点 捷克文 25-11-2020
公众评估报告 公众评估报告 捷克文 21-03-2019
资料单张 资料单张 丹麦文 25-11-2020
产品特点 产品特点 丹麦文 25-11-2020
公众评估报告 公众评估报告 丹麦文 21-03-2019
资料单张 资料单张 德文 25-11-2020
产品特点 产品特点 德文 25-11-2020
公众评估报告 公众评估报告 德文 21-03-2019
资料单张 资料单张 爱沙尼亚文 25-11-2020
产品特点 产品特点 爱沙尼亚文 25-11-2020
公众评估报告 公众评估报告 爱沙尼亚文 21-03-2019
资料单张 资料单张 希腊文 25-11-2020
产品特点 产品特点 希腊文 25-11-2020
公众评估报告 公众评估报告 希腊文 21-03-2019
资料单张 资料单张 法文 25-11-2020
产品特点 产品特点 法文 25-11-2020
公众评估报告 公众评估报告 法文 21-03-2019
资料单张 资料单张 意大利文 25-11-2020
产品特点 产品特点 意大利文 25-11-2020
公众评估报告 公众评估报告 意大利文 21-03-2019
资料单张 资料单张 拉脱维亚文 25-11-2020
产品特点 产品特点 拉脱维亚文 25-11-2020
公众评估报告 公众评估报告 拉脱维亚文 21-03-2019
资料单张 资料单张 立陶宛文 25-11-2020
产品特点 产品特点 立陶宛文 25-11-2020
公众评估报告 公众评估报告 立陶宛文 21-03-2019
资料单张 资料单张 匈牙利文 25-11-2020
产品特点 产品特点 匈牙利文 25-11-2020
公众评估报告 公众评估报告 匈牙利文 21-03-2019
资料单张 资料单张 马耳他文 25-11-2020
产品特点 产品特点 马耳他文 25-11-2020
公众评估报告 公众评估报告 马耳他文 21-03-2019
资料单张 资料单张 荷兰文 25-11-2020
产品特点 产品特点 荷兰文 25-11-2020
公众评估报告 公众评估报告 荷兰文 21-03-2019
资料单张 资料单张 波兰文 25-11-2020
产品特点 产品特点 波兰文 25-11-2020
公众评估报告 公众评估报告 波兰文 21-03-2019
资料单张 资料单张 葡萄牙文 25-11-2020
产品特点 产品特点 葡萄牙文 25-11-2020
公众评估报告 公众评估报告 葡萄牙文 21-03-2019
资料单张 资料单张 罗马尼亚文 25-11-2020
产品特点 产品特点 罗马尼亚文 25-11-2020
公众评估报告 公众评估报告 罗马尼亚文 21-03-2019
资料单张 资料单张 斯洛伐克文 25-11-2020
产品特点 产品特点 斯洛伐克文 25-11-2020
公众评估报告 公众评估报告 斯洛伐克文 21-03-2019
资料单张 资料单张 斯洛文尼亚文 25-11-2020
产品特点 产品特点 斯洛文尼亚文 25-11-2020
公众评估报告 公众评估报告 斯洛文尼亚文 21-03-2019
资料单张 资料单张 芬兰文 25-11-2020
产品特点 产品特点 芬兰文 25-11-2020
公众评估报告 公众评估报告 芬兰文 21-03-2019
资料单张 资料单张 瑞典文 25-11-2020
产品特点 产品特点 瑞典文 25-11-2020
公众评估报告 公众评估报告 瑞典文 21-03-2019
资料单张 资料单张 挪威文 25-11-2020
产品特点 产品特点 挪威文 25-11-2020
资料单张 资料单张 冰岛文 25-11-2020
产品特点 产品特点 冰岛文 25-11-2020
资料单张 资料单张 克罗地亚文 25-11-2020
产品特点 产品特点 克罗地亚文 25-11-2020
公众评估报告 公众评估报告 克罗地亚文 21-03-2019

搜索与此产品相关的警报

查看文件历史